Enzalutamide (Xtandi) is a drug which blocks the effect of the hormone testosterone on the prostate and so slows down the growth of the cancer. Enzalutamide is taken as four capsules once a day. If licenced in the UK, it could provide an additional treatment option for patients with non-metastatic prostate cancer
Enzalutamide (Xtandi) for non-metastatic prostate cancer
Interventions:
Enzalutamide (Xtandi; MDV3100)
Indications:
Prostate cancer
Therapeutic Areas:
Male Reproductive Cancer
Year:
2017